Societe Generale’s Orexigen Therapeutics, Inc. OREX Stock Holding History

Societe Generale’s Portfolio OREX Stock Details OREX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	$21K	Buy	+4,833	New	+$21.9K	﹤0.01%	2508

Other funds holding OREX

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

Tiverton Asset Management Wilimington, Delaware $2.88B AUM 5.6% 1-Year Est. Return

Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Societe Generale's OREX Position: Q2 2016 in Review

Societe Generale opened a new position in Orexigen Therapeutics, Inc. (OREX) in Q2 2016: 4,833 shares worth $21K. The stake represents ﹤0.01% of the portfolio and ranks #2508 among its holdings.

73 funds tracked by Wall St. Rank hold OREX as of Q2 2016.

Societe Generale held 4,833 shares of Orexigen Therapeutics, Inc. worth $21K as of Q2 2016.
Orexigen Therapeutics, Inc. was a new Societe Generale position in Q2 2016.
Orexigen Therapeutics, Inc. made up ﹤0.01% of Societe Generale's portfolio in Q2 2016, its #2508 holding.
73 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q2 2016.

Based on Societe Generale's 13F filing for Q2 2016, filed 2 Aug 2016.